Stephens Inc. AR Grows Stock Position in Eli Lilly And Co (NYSE:LLY)

Stephens Inc. AR raised its stake in shares of Eli Lilly And Co (NYSE:LLY) by 16.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 42,419 shares of the company’s stock after acquiring an additional 5,970 shares during the period. Stephens Inc. AR’s holdings in Eli Lilly And Co were worth $4,744,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bessemer Group Inc. grew its position in shares of Eli Lilly And Co by 2,354.5% during the 2nd quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock valued at $63,096,000 after acquiring an additional 546,307 shares during the period. Cedar Capital LLC grew its position in shares of Eli Lilly And Co by 17.5% during the 2nd quarter. Cedar Capital LLC now owns 2,459 shares of the company’s stock valued at $272,000 after acquiring an additional 367 shares during the period. Assetmark Inc. grew its position in shares of Eli Lilly And Co by 13.9% during the 2nd quarter. Assetmark Inc. now owns 410,334 shares of the company’s stock valued at $45,461,000 after acquiring an additional 50,087 shares during the period. Haverford Trust Co. grew its position in shares of Eli Lilly And Co by 60.3% during the 2nd quarter. Haverford Trust Co. now owns 6,418 shares of the company’s stock valued at $711,000 after acquiring an additional 2,414 shares during the period. Finally, Naples Global Advisors LLC grew its position in shares of Eli Lilly And Co by 1.1% during the 2nd quarter. Naples Global Advisors LLC now owns 15,591 shares of the company’s stock valued at $1,727,000 after acquiring an additional 170 shares during the period. Institutional investors and hedge funds own 76.75% of the company’s stock.

A number of equities research analysts have recently commented on the company. Bank of America assumed coverage on Eli Lilly And Co in a research report on Wednesday, October 16th. They set a “buy” rating and a $133.00 target price on the stock. UBS Group lowered their price objective on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a report on Thursday, October 17th. Finally, ValuEngine cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, June 28th. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Eli Lilly And Co currently has a consensus rating of “Buy” and an average price target of $127.69.

In other news, SVP Alfonso G. Zulueta sold 19,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total transaction of $2,201,745.00. Following the transaction, the senior vice president now directly owns 38,306 shares in the company, valued at approximately $4,325,130.46. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 4,500 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $117.00, for a total value of $526,500.00. Following the transaction, the senior vice president now owns 33,806 shares in the company, valued at $3,955,302. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 243,452 shares of company stock worth $28,252,925. Insiders own 0.11% of the company’s stock.

LLY stock opened at $111.08 on Tuesday. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 4.98. Eli Lilly And Co has a 12-month low of $104.17 and a 12-month high of $132.13. The stock has a market cap of $104.88 billion, a price-to-earnings ratio of 20.01, a PEG ratio of 1.85 and a beta of 0.16. The business’s 50-day moving average is $110.93 and its 200 day moving average is $113.71.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The company had revenue of $5.64 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm posted $1.48 EPS. Eli Lilly And Co’s revenue was up .9% compared to the same quarter last year. As a group, equities analysts forecast that Eli Lilly And Co will post 5.73 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $0.645 dividend. This represents a $2.58 annualized dividend and a yield of 2.32%. Eli Lilly And Co’s payout ratio is 46.49%.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: How Do I Invest in Dividend Stocks

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.